Browse > Article
http://dx.doi.org/10.5352/JLS.2007.17.4.515

Effect of Low Dose Administration of Aprotinin in Pump Priming Solution on Cardiac Surgery  

Moon, Seong-Min (Laboratory of Extracorporeal Circulation, Department of Thoracic and Cardiovascular Surgery, Dong-A University Medical Center, College of Medicine, Dong-A University)
Choi, Seok-Cheol (Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan)
Publication Information
Journal of Life Science / v.17, no.4, 2007 , pp. 515-521 More about this Journal
Abstract
Aprotinin, a serine protease inhibitor, has been used to ameliorate the inevitable consequences, including blood component injury after cardiac surgery with cardiopulmonary bypass (CPB). However, there are many arguments on its dosage or usage. We assessed whether administration of low dose of aprotinin in only priming solution has any beneficial effect or reduces its side effects on cardiac surgery. Thirty patients scheduled for elective cardiac surgery were randomly assigned to aprotinin group (n=15) which received aprotinin in priming solution (two million kallikrein inhibitory unit, KIU) and added one million KIU at 1 hour after the beginning of CPB or control group (n=15) which did not receive it. Hematological and biochemical variables, cytokines and cardiac marker levels, and postoperative outcomes were compared between two groups at before, during or after operation. Platelet count in aprotinin group was higher than that of control group at postoperative 24 hr. Activated partial thromboplastin time in aprotinin group was longer than that of control group at intensive care unit (ICU). Troponin-I level and postoperative blood loss volumes in aprotinin group were lower than those of control group at ICU. There were no significant differences between the two groups on the others. These results showed that low dosage of only priming solution during cardiac surgery with CPB reduced platelet destruction and postoperative bleeding, and attenuates myocardial damage. However, further studies need to be carried out with more population or pediatric patients for evaluating various aprotinin usage.
Keywords
Cardiac surgery; cardiopulmonary bypass; aprotinin;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Westaby, S. 1993. Aprotinin in perspective. Ann. Thorac. Surg. 55, 1033-1041   DOI   ScienceOn
2 Wippermann, C. F., F. X. Schmid and B. Eberle. 1999. Reduced inotrpic support after aprotinin therapy during pediatric cardiac operations. Ann. Thorac. Surg. 67, 173-176   DOI   ScienceOn
3 Gurevith, J., J. Barak, E. Hochhauser, Y. Paz and V. Yakirevich. 1994. Aprotinin improves myocardial recovery after ischemia and reperfusion: Effects of the drug on isolated rat hearts. J. Thorac. Cardiovasc. Surg. 108, 109-118
4 Liu, B., L. Tengborn and G. Larson. 1995. Half-dose aprotinin preserve hemostatic function in patient undergoing bypass operations. Ann. Thorac. Surg. 59, 1534-1540   DOI   ScienceOn
5 McMahon, M. J. and A. T. R. Axon. 1984. Anaphylactic reaction to aprotinin. Br. J. Med. 289, 1696
6 Royston, D., B. P. Bidstrup, K. M. Taylor and R. N. Sapsford. 1987. Effect of aprotinin on need for blood transfusion after repeat open heart surgery. Lancet 2, 1289-1291
7 Shin, Y. C., T. K. Cheon, Y. S. Won, Y. J Kim and J. R. Rho. 1996. Effect of aprotinin on postoperative bleeding and blood coagulation system in pediatric open heart surgery. Kor. J. Thorac. Cardiovasc. Surg. 29, 303-310
8 Sunamori, M., I. Sultan and A. Suzuki. 1991. Effect of aprotinin to improve myocardial viability in myocardial preservation followed by reperfusion. Ann. Thorac. Surg. 52, 971-9   DOI   ScienceOn
9 Sundt, T. M., N. T. Kouchoukos and J. E. Saffitz. 1993. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann. Thorac. Surg. 55, 1418-1424   DOI   ScienceOn
10 Ulker, S., P. P. Mckeown and U. Bayraktutan. 2002. Aprotinin impairs coronary endothelial function and down-regulates endothelial NOs in rat coronary microvascular endothelial cells. Cardiovascular Research 55, 830-837   DOI   ScienceOn
11 van Oeveren, W., M. P. Harder, K. J. Roozendaal, L. Eijsman and C. R. Wildevuur. 1990. Aprotinin products platelet against the initial effect of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 99, 788-797
12 Wachtfogel, Y. T., U. Kucich and C. E. Hack. 1993. Aprotinin inhibits the contact, neutrophil and platelet activation systems, during simulated extracorporeal perfusion. J. Thorac. Cardiovasc. Surg. 106, 1-10
13 Covino, E., D. Pepino, D. Iorio, L. Marino, P. Ferrara and N. Spampinalo. 1991. Low dose aprotinin as blood saver in open heart surgery. Eur. J. Cardiothorac. Surg. 5, 619-624
14 Ashraf, S., Y. Tian and D. Cowan. 1997. 'Low-dose' aprotinin modifies hemostasis but not proinfIammatory cytokine release. Ann. Thorae. Surg. 63, 68-73   DOI   ScienceOn
15 Baufreton, C., H. Velthuis, P. G. M. Jansen, P. Lebesnerais, C. H. R. Wildevuur and D. Y. Loisance. 1996. Reduction of blood activation in patients requiring aprotinin during cardiopulmonary bypass for coronary artery surgery. ASAlO. J. 42:M, 417-423   DOI   ScienceOn
16 Boher, H., A. Bach, F. Fleicher and J. Lang. 1990. Adverse haemodynamic effects of high-dose aprotinin in a paediatric cardiac surgical patients. Anaesthesia 45, 853-854   DOI   ScienceOn
17 Defraigne, J. O., J. Pincemail, R. Larbuisson, F. Blaffart and R. Limet. 2000. Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. Ann. Thorac. Surg. 69, 1084-1091   DOI   ScienceOn
18 Harder, M. P., L. Eijsman, K. J. Roozendal, W. van Oevern and C. R. Wildevuur. 1991. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann. Thorac. Surg. 51, 936-941   DOI   ScienceOn
19 Kawasuji, M., K. Ueyama and S. Naoki. 1993. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann. Thorac. Surg. 55, 1205-1209   DOI   ScienceOn